A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-±, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
申请公布号
EP2594562(A2)
申请公布日期
2013.05.22
申请号
EP20130154949
申请日期
2008.05.30
申请人
GENZYME CORPORATION
发明人
SIEGEL, CRAIG;BASTOS, CECILIA M;HARRIS, DAVID J;LEE, EDWARD;SILVA, RICHARD;CUFF, LISA M;LEVINE, MIKAELA;CELATKA, CASSANDRA;VINICK, FREDERIC;JOZEFIAK, THOMAS;XIANG, YIBIN;KANE, JOHN;DIOS, ANGELES;LIAO, JUNKAI